Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
ATP citrate lyase (ACL) catalyzes the synthesis of acetyl-CoA and oxaloacetate using citrate, CoA, and ATP as substrates and Mg2+ as a cofactor.1 The ACL-dependent synthesis of acetyl-CoA is important for the de novo synthesis of fatty acids and cholesterol.2 Furthermore, as a key enzyme for linking glucose and lipid metabolism, ACL is thought to contribute to the Warburg effect in cancer cells.3 BMS 303141 is a cell-permeable, 2-hydroxy-N-arylbenzenesulfonamide that inhibits ACL with an IC50 value of 0.13 µM.4 At an oral dose of 100 mg/kg/day, BMS 303141 has been reported to reduce weight gain and lower plasma cholesterol, triglycerides, and glucose in a mouse model of hyperlipidemia.4
WARNING This product is not for human or veterinary use.
1. A novel direct homogeneous assay for ATP citrate lyase. J. Lipid Res. 50(10), 2131-2135 (2009).
2. Glucose-
3. ATP citrate lyase inhibitors as novel cancer therapeutic agents. Recent Pat.Anticancer Drug Discov. 7(2), 154-167 (2012).
4. 2-